Sonia Brockway

Sonia Brockway

Auto-generated profile, based on publicly available information

Sonia Brockway

Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2015 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
MPM E Peter
M E Peter
AHA Hadji
A Hadji
AMA E Murmann
A E Murmann
SBS Brockway
S Brockway
WPW Putzbach
W Putzbach
PCPaolo Ceppi
Paolo Ceppi
CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy.

1 March 2017 in Cell Reports
Verified
Journal Article
Open access
AQAbdul S. Qadir
Abdul S. Qadir
PCPaolo Ceppi
Paolo Ceppi
SBSonia Brockway
Sonia Brockway
CLCalvin Law
Calvin Law
LMLiang Mu
Liang Mu
MPMarcus E. Peter
Marcus E. Peter
Stimulation of CD95/Fas drives and maintains cancer stem cells (CSCs). We now report that this involves activation of signal transducer and activator of transcription 1 (STAT1) and induction of STAT1-regulated genes and that this process is inhibited by active caspases. STAT1 is enriched in CSCs in cancer cell lines, patient-derived human breast cancer, and CD95high-expressing glioblastoma neurospheres. CD95 stimulation of cancer cells induced secretion of type I interferons (IFNs) that bind to type I IFN receptors, resulting in activation of Janus-activated kinases, activation of STAT1, and induction of a number of STAT1-regulated genes that are part of a gene signature recently linked to therapy resistance in five primary human cancers. Consequently, we identified type I IFNs as drivers of cancer stemness. Knockdown or knockout of STAT1 resulted in a strongly reduced ability of CD95L or type I IFN to increase cancer stemness. This identifies STAT1 as a key regulator of the CSC-inducing activity of CD95.

1 April 2014 in Cell Reports
Verified
Journal Article
Open access
AHAbbas Hadji
Abbas Hadji
PCPaolo Ceppi
Paolo Ceppi
AMAndrea E. Murmann
Andrea E. Murmann
SBSonia Brockway
Sonia Brockway
APAbhinandan Pattanayak
Abhinandan Pattanayak
MPMarcus E. Peter
Marcus E. Peter
CD95 (Fas/APO-1), when bound by its cognate ligand CD95L, induces cells to die by apoptosis. We now show that elimination of CD95 or CD95L results in a form of cell death that is independent of caspase-8, RIPK1/MLKL, and p53, is not inhibited by Bcl-xL expression, and preferentially affects cancer cells. All tumors that formed in mouse models of low-grade serous ovarian cancer or chemically induced liver cancer with tissue-specific deletion of CD95 still expressed CD95, suggesting that cancer cannot form in the absence of CD95. Death induced by CD95R/L elimination (DICE) is characterized by an increase in cell size, production of mitochondrial ROS, and DNA damage. It resembles a necrotic form of mitotic catastrophe. No single drug was found to completely block this form of cell death, and it could also not be blocked by the knockdown of a single gene, making it a promising way to kill cancer cells.

18 March 2022 in Science Advances
Verified
Journal Article
Open access
RSRoger S. Smith
Roger S. Smith
STSeesha R. Takagishi
Seesha R. Takagishi
DADavid R. Amici
David R. Amici
KMKyle Metz
Kyle Metz
SGSitaram Gayatri
Sitaram Gayatri
MMMarc L. Mendillo
Marc L. Mendillo
Heat shock factor 1 (HSF1) is well known for its role in the heat shock response (HSR), where it drives a transcriptional program comprising heat shock protein (HSP) genes, and in tumorigenesis, where it drives a program comprising HSPs and many noncanonical target genes that support malignancy. Here, we find that HSF2, an HSF1 paralog with no substantial role in the HSR, physically and functionally interacts with HSF1 across diverse types of cancer. HSF1 and HSF2 have notably similar chromatin occupancy and regulate a common set of genes that include both HSPs and noncanonical transcriptional targets with roles critical in supporting malignancy. Loss of either HSF1 or HSF2 results in a dysregulated response to nutrient stresses in vitro and reduced tumor progression in cancer cell line xenografts. Together, these findings establish HSF2 as a critical cofactor of HSF1 in driving a cancer cell transcriptional program to support the anabolic malignant state.

4 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAndrea E. Murmann
Andrea E. Murmann
KMKaylin M. McMahon
Kaylin M. McMahon
AHAshley Haluck-Kangas
Ashley Haluck-Kangas
NRNandini Ravindran
Nandini Ravindran
MPMonal Patel
Monal Patel
MPMarcus E. Peter
Marcus E. Peter
The death receptor CD95/Fas can be activated by immune cells to kill cancer cells. shRNAs and siRNAs derived from CD95 or CD95 ligand (CD95L) are highly toxic to most cancer cells. We recently found that these sh/siRNAs kill cancer cells in the absence of the target by targeting the 3’UTRs of critical survival genes through canonical RNAi. We have named this unique form of off-target effect DISE (for death induced by survival gene elimination). DISE preferentially kills transformed cells and cancer stem cells. We demonstrate that DISE induction occurs in cancer cells in vivo after introducing a lentiviral CD95L derived shRNA (shL3) into HeyA8 ovarian cancer cells grown as i.p. xenografts in mice, when compared to a scrambled shRNA. To demonstrate the possibility of therapeutically inducing DISE, we coupled siRNAs to templated lipoprotein nanoparticles (TLP). In vitro, TLPs loaded with a CD95L derived siRNA (siL3) selectively silenced a biosensor comprised of Venus and CD95L ORF and killed ovarian cancer cells. In vivo, two siRNA-TLPs (siL2-TLP and siL3-TLP) reduced tumor growth similarly as observed for cells expressing the shL3 vector. These data suggest that it is possible to kill ovarian cancer cells in vivo via DISE induction using siRNA-TLPs.

1 May 2015 in Cancer Genetics
Verified
Journal Article
Closed access
SBSonia Brockway
Sonia Brockway
NZNancy J. Zeleznik-Le
Nancy J. Zeleznik-Le